Ubiquitin Ligase (E3) Inhibitors: Products

(+)-JQ1 based Degrader (PROTAC®) that preferentially degrades BRD4

MDM2 antagonist; inhibits MDM2-p53 interaction

Cereblon binder; induces ubiquitination and degradation of CK1α by E3 ubiquitin ligase

Potent and selective CSN5 (COP9 signalosome) inhibitor

Cdc20 inhibitor; inhibits Cdc20-substrate interaction

MDM2 antagonist; active enantiomer of Nutlin-3 (Cat. No. 3984)

High-affinity inhibitor of VHL

Cereblon binder; also TNF-α inhibitor and antiangiogenic

(+)-JQ1 based Degrader (PROTAC®) targeting BET bromodomains, active in vivo

Molecular glue; pre-mRNA splicing modulator

Potent and selective cereblon Degrader (PROTAC®); cell-permeable

MDM2-p53 interaction inhibitor

Hdm2 inhibitor; activates p53-dependent transcription

Selective inhibitor of E3 ubiquitin ligase

Inhibitor of Bmi1/Ring1A; blocks histone H2A ubiquitination

Selective Skp2 inhibitor; suppresses E3 ligase activity

Protects against α-synuclein toxicity; promotes Rsp5/Nedd4-dependent endosomal transport

Bmi-1 inhibitor; antitumor

High affinity MDM2 inhibitor

High affinity Smurf1 inhibitor; enhances BMP signaling

β-TrCP1 ligase inhibitor

HECT E3 ubiquitin ligase inhibitor

Negative control for VH 298

(+)-JQ1 based PROTAC® with selectivity for BRD4

Homo-PROTAC® for self-degradation of pVHL30

Multikinase Degrader (PROTAC®)

Negative control for TL 12-186 (Cat. No. 6524)

Promotes survival of muscle stem cells (MuSCs); MDM2 inhibitor; activates p53 activity

Potent MDM2 inhibitor; inhibits MDM2-p53 interaction

Potent, selective and reversible DCN1-UBC12 interaction inhibitor

SKP2 (S-phase kinase-associated protein 2) inhibitor; upregulates p27 and arrests cell cycle in G1 phase

RNF114 inhibitor

Covalent RNF114 ligand

SPOP E3 ubiquitin ligase inhibitor

Negative control for CSN5i-3 (Cat. No. 7089)

MAGE-A11 inhibitor disrupts MAGE-A11:PCF11 interaction

TRAF6-Ubc13 interaction inhibitor

Inhibitor of VHL; blocks interaction of VHL and HIF-α